Oral Squamous Cell Carcinoma Clinical Trial
— PRV111Official title:
Phase 1/2, Open-Label, Single-Arm Safety and Efficacy Dose-Finding, Systemic Exposure, and Device Technical Effects of PRV111 (Cisplatin Transmucosal System) in Subjects With Oral Squamous Cell Carcinoma
Verified date | September 2022 |
Source | Privo Technologies |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Up to 31 subjects diagnosed with oral squamous cell carcinoma received one application of a permeation enhancer 3 treatment applications of a Cisplatin drug-loaded patch to the tumor site at each of the 4 treatment visits. These 4 treatment visits were scheduled to occur during the 3 weeks prior to the standard of care tumor resection. Funding Source: FDA OOPD
Status | Completed |
Enrollment | 10 |
Est. completion date | May 6, 2020 |
Est. primary completion date | October 27, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Pathologically confirmed T1 (<2 cm) or T2 (>2 cm but < or = 4 cm) squamous cell carcinoma (SCC) of the lip or oral cavity (anterior 2/3 of the tongue, floor of mouth, lower and upper gingiva, salivary gland, hard palate, and buccal mucosa). 2. Tumor must be easily accessible, with no evidence of infection or active bleeding, encroaching major vessels or clinical evidence of neural invasion. Not previously irradiated. 3. Tumors must be amenable to surgical resection no later than 21 days post Visit 1. 4. Clinically or radiologically measurable tumor. 5. ECOG Performance Status of < or =2. 6. Adequate renal function as demonstrated by renal creatinine clearance. 7. Adequate organ function as assessed by safety labs. 8. Agree to use effective contraception for 30 days after the last dose of study drug. 9. Absence of any serious medical conditions that would impair the subject's ability to participate. 10. Willing and able to provide written informed consent. 11. Able to return to the study site for treatment and follow-up visits as defined in the protocol. Exclusion Criteria: 1. Known distal metastasis of the SCC of the oral cavity. 2. Systemic chemotherapy for the treatment of SCC of the head and neck less than 2 years prior to screening. 3. Concurrent documented malignancy, with the exception of localized SCC of the skin. 4. Exposure to any investigational agent within 3 months prior to screening. 5. Known allergy or hypersensitivity to platinum-containing agents. 6. Active, uncontrolled infection requiring systemic therapy. 7. Known or suspected pregnancy, planned pregnancy or lactation. |
Country | Name | City | State |
---|---|---|---|
United States | University of Cincinnati Cancer Institute | Cincinnati | Ohio |
United States | Ben Taub Hospital | Houston | Texas |
United States | Memorial Hermann Hospital | Houston | Texas |
United States | The University of Texas Health Science Center School of Dentistry | Houston | Texas |
United States | Advanced ENT and Allergy | Louisville | Kentucky |
Lead Sponsor | Collaborator |
---|---|
Privo Technologies | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine an Efficacious Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Tumor Responses | The starting dose was 1.5 mg/cm2 of cisplatin. Based on the incidence of dose-limiting toxicities and tumor response, subjects would either continue to receive the starting dose or the dose would be de-escalated to 1.0 mg/cm2 or escalated to 2.5 mg/cm2.
This measures presents the number of tumor responses during the PRV111 treatment period |
Subjects were evaluated for efficacy during the 4 treatment visits in the 21 days prior to surgery | |
Primary | Determine a Safe Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Dose-Limiting Toxicities | The starting dose was 1.5 mg/cm2 of cisplatin. Based on the incidence of dose-limiting toxicities and tumor response, subjects would either continue to receive the starting dose or the dose would be de-escalated to 1.0 mg/cm2 or escalated to 2.5 mg/cm2.
This measures presents the number of reported dose-limiting toxicities during the PRV111 treatment period |
4 treatment visits in the 21 days prior to surgery | |
Secondary | Tumor Response (Tumor Volume Change From Baseline and Pre-op Visit, Approximately 21 Days Prior to Surgical Excision of the Tumor) | Assessed by clinical measurement at baseline and at the pre-op visit | Assessed within the 21 days prior to surgical excision of the tumor | |
Secondary | Number of Loco-regional Recurrences | Number of loco-regional recurrences at follow-up | Assessed 1, 3 and 6 months post surgery | |
Secondary | Tumor and Lymph Node (if Available) Platinum Levels | Levels of platinum content in tumor tissue and/or lymph tissue, using a validated bioanalytical ICP-MS method. Resected tissues were digested via microwave and used to evaluate the amount of cisplatin delivered by PRV111 (Correlated to the amount of platinum detected). | 21 days from baseline through surgical excision of the tumor | |
Secondary | Technical Success - Residual Cisplatin Levels Post-application | Platinum content in each residual PRV111, using a validated bioanalytical ICP-MS method and the results for all applications were averaged. | 4 treatment visits in the 21 days prior to surgery | |
Secondary | Systemic Platinum Levels (Cmax) | Levels of platinum content in blood, using a validated bioanalytical ICP-MS method. Blood drawn was digested via microwave and used to evaluate the amount of systemic cisplatin exposure from PRV111 (Correlated to the amount of platinum detected). A single value for Cmax was calculated by averaging values for all subjects. | Cmax is a single value of the highest concentration of platinum in the blood reported from samples taken post-dose across all 4 treatment visits (Baseline [0], 30, 60, and 120 minutes at Visits 1-4) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04543266 -
Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning
|
||
Not yet recruiting |
NCT06438939 -
NBI for Early Diagnosis of OPMD/OSCC
|
N/A | |
Recruiting |
NCT05024383 -
Dissecting the Heterogeneity of Oral Cancer Pain
|
N/A | |
Recruiting |
NCT06031337 -
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
|
||
Not yet recruiting |
NCT06174428 -
Validity of Viome's Oral/Throat Cancer Test
|
||
Recruiting |
NCT05098119 -
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
|
Phase 2 | |
Recruiting |
NCT05069857 -
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
|
Phase 2 | |
Not yet recruiting |
NCT03619304 -
Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line
|
N/A | |
Active, not recruiting |
NCT01772706 -
Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05893888 -
Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05125055 -
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06055868 -
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
|
||
Not yet recruiting |
NCT06130007 -
A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.
|
Phase 2 | |
Recruiting |
NCT05798793 -
Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma
|
Phase 3 | |
Recruiting |
NCT02739204 -
Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT05708209 -
The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124
|
||
Recruiting |
NCT05862168 -
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma :A Single-arm, Prospective, Phase II Trial
|
Phase 2 | |
Recruiting |
NCT05451303 -
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
|
||
Recruiting |
NCT05902455 -
Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
|
||
Not yet recruiting |
NCT05803915 -
Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
|
Phase 2 |